XWPHARMA

XWPharma is a clinical-stage biopharmaceutical company focused on the discovery and development of central nervous system (CNS) therapeutics. According to its official website, the company applies novel platform chemistry to time-regulated neurobiology, with the goal of providing patients with hope in times of need. Its approach centers on mechanisms of action that have already been validated as highly effective in clinical studies and medical practice, and it seeks to leverage time-regulated neurobiology to achieve efficacy without the limitations associated with currently available treatments. The company's pipeline is led by valilxoybate, a GABA B agonist new chemical entity (NCE) being developed for narcolepsy and the non-motor symptoms of Parkinson's disease. Narcolepsy is described as a life-long disease characterized by fragmented sleep, manifesting primarily as excessive daytime sleepiness (EDS) and cataplexy, a sudden and uncontrollable muscle weakness or paralysis. XWPharma notes that narcolepsy is considered an orphan disease in the United States, affecting an estimated 165,000 to 185,000 people, and that GABA B agonists indicated for the treatment of narcolepsy currently represent close to $2.0 billion in US annual sales. XWPharma employs several strategies across all of its programs to increase the odds that its internally discovered medicines will succeed in clinical testing and commercialization. It focuses its proprietary drug discovery methodology on mechanisms of action that are validated as highly effective in clinical studies and medical practice. It pursues efficient development pathways designed to de-risk each program at an early stage of clinical development. Each therapy targets high-value commercial markets with favorable reimbursement and market access. All of the company's therapies in clinical development are new chemical entities with distinctive features and composition-of-matter intellectual property. As a clinical-stage company, XWPharma is privately held and does not disclose a stock ticker. Its operations are centered on drug discovery and clinical development rather than commercial-stage manufacturing or sales. The company maintains a website at xwpharma.com that presents its approach, pipeline, team, and media contact information.

XWPharma is a clinical-stage biopharmaceutical company dedicated to the discovery and development of CNS therapeutics. Public information about the company is primarily available through its official website, which describes its scientific approach, pipeline, team, and media contact. The company applies novel platform chemistry to time-regulated neurobiology, a strategy intended to achieve efficacy without the limitations associated with currently available treatments. XWPharma's drug discovery methodology focuses on mechanisms of action that are validated as highly effective in clinical studies and medical practice. The company states that it pursues efficient development pathways designed to de-risk each program at an early stage of clinical development, and that each therapy targets high-value commercial markets with favorable reimbursement and market access. All of its therapies in clinical development are new chemical entities with distinctive features and composition-of-matter intellectual property. The company's lead program is valilxoybate, a GABA B agonist NCE being developed for narcolepsy and the non-motor symptoms of Parkinson's disease. Narcolepsy is a life-long disease characterized by fragmented sleep, manifesting primarily as excessive daytime sleepiness (EDS) and cataplexy. XWPharma notes that narcolepsy is considered an orphan disease in the United States, affecting an estimated 165,000 to 185,000 people, and that GABA B agonists indicated for treatment of narcolepsy currently represent close to $2.0 billion in US annual sales. As a clinical-stage company, XWPharma is privately held and does not disclose a stock ticker. Its operations are centered on drug discovery and clinical development rather than commercial-stage manufacturing or sales. The company maintains a website at xwpharma.com that presents its approach, pipeline, team, and media contact information.

Clinical-stage CNS-focused biopharmaceutical company applying novel platform chemistry to time-regulated neurobiology, targeting validated mechanisms of action and high-value commercial markets.

• valilxoybate

  A GABA B agonist new chemical entity (NCE) in clinical development for narcolepsy and non-motor symptoms of Parkinson's disease.

1. 1XWPharmaxwpharma.com
2. 2XWPHARMAwikidata.org